Formations Gestion Analyses CAC et StratÃ©gies de Trading

CNS: Fenetresurcours: NewsRenderer

Today is June 02, 2024. All times in Eastern Daylight Time.

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

06/02/2024 - 05:30 PM

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bis... more »
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

06/02/2024 - 02:32 PM

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meanin... more »
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination

06/02/2024 - 12:30 PM

MUNICH--(BUSINESS WIRE)--CatalYm today announced positive new follow-up results from its ongoing “GDFATHER” Phase 1/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1/2a) (NC... more »
Stronger Than Ever: Adani Portfolio Delivers Record Performance

06/02/2024 - 12:09 PM

AHMEDABAD, India--(BUSINESS WIRE)--Adani Portfolio’s Credit and Result compendium for financial year 2023-24 signify its businesses' strength, stability, and robustness. more »
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

06/02/2024 - 10:56 AM

PHILADELPHIA--(BUSINESS WIRE)--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma more »
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

06/02/2024 - 10:01 AM

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting. more »
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

06/02/2024 - 09:30 AM

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumo... more »
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing

06/02/2024 - 09:00 AM

SECAUCUS, N.J.--(BUSINESS WIRE)--ZT Systems, a leading provider of accelerated computing solutions for artificial intelligence (AI) and cloud, today announced its ACX200 platform featuring the NVID... more »
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises

06/02/2024 - 08:30 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises. more »
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI

06/02/2024 - 08:30 AM

RIYADH, Saudi Arabia--(BUSINESS WIRE)--Denodo Opens ME regional head office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI more »
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

06/02/2024 - 08:05 AM

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful imp... more »
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

06/02/2024 - 08:00 AM

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 s... more »
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

06/02/2024 - 08:00 AM

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 s... more »
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy

06/02/2024 - 08:00 AM

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy more »
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe

06/02/2024 - 08:00 AM

CHICAGO--(BUSINESS WIRE)--ASCO Annual Meeting – Massive Bio, a renowned leader in AI-driven oncology solutions and Mika Health, the premier oncology digital therapeutic platform, today announced a ... more »

1 2 3 4 5 6 7 8 9 10 11 ... 1000